UY34105A - Formulación líquida estable de etanercept - Google Patents

Formulación líquida estable de etanercept

Info

Publication number
UY34105A
UY34105A UY0001034105A UY34105A UY34105A UY 34105 A UY34105 A UY 34105A UY 0001034105 A UY0001034105 A UY 0001034105A UY 34105 A UY34105 A UY 34105A UY 34105 A UY34105 A UY 34105A
Authority
UY
Uruguay
Prior art keywords
etanercept
liquid formulation
stable liquid
stable
formulation
Prior art date
Application number
UY0001034105A
Other languages
English (en)
Inventor
Choi Suk Young
Ko Youn Kyung
So Jin Eon
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of UY34105A publication Critical patent/UY34105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Formulación líquida estable de etanercept (proteína de fusión sTNFR:Fc p75 recombinante), y más específicamente, una formulación líquida que comprende uno o más estabilizantes seleccionados del grupo que consiste de metionina, lisina, histidina, así como las sales de las mismas aceptables desde el punto de vista farmacéutico en una cantidad suficiente para reducir la formación de los subproductos de etanercept durante el almacenamiento. La formulación líquida de acuerdo con la presente invención reduce de manera efectiva la producción de los subproductos de etanercept y mantiene en forma estable sus eficacias farmacéuticas durante el almacenamiento por largos periodos de tiempo.
UY0001034105A 2011-06-03 2012-05-29 Formulación líquida estable de etanercept UY34105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20110053890 2011-06-03

Publications (1)

Publication Number Publication Date
UY34105A true UY34105A (es) 2012-07-31

Family

ID=46690924

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034105A UY34105A (es) 2011-06-03 2012-05-29 Formulación líquida estable de etanercept

Country Status (26)

Country Link
US (1) US10258689B2 (es)
EP (1) EP2714009B1 (es)
JP (2) JP5918850B2 (es)
KR (2) KR101482304B1 (es)
CN (2) CN103619324A (es)
AR (1) AR086658A1 (es)
AU (1) AU2012263100B2 (es)
BR (1) BR112013031112A8 (es)
CA (1) CA2837176C (es)
CL (1) CL2013003461A1 (es)
CO (1) CO6852068A2 (es)
EA (1) EA028947B1 (es)
ES (1) ES2645969T3 (es)
HK (1) HK1204921A1 (es)
HU (1) HUE037031T2 (es)
IL (1) IL229787A (es)
MA (1) MA35186B1 (es)
MX (1) MX354297B (es)
MY (1) MY173907A (es)
SG (1) SG195054A1 (es)
TN (1) TN2013000493A1 (es)
TW (2) TW201540322A (es)
UA (1) UA113172C2 (es)
UY (1) UY34105A (es)
WO (1) WO2012165917A1 (es)
ZA (1) ZA201308659B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AU2012326171B2 (en) * 2011-10-18 2017-03-09 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CA2878508A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
JP2014214153A (ja) * 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
WO2014177548A1 (en) * 2013-05-02 2014-11-06 Mabxience, S.A. Alternative formulations for tnfr: fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
WO2015080513A1 (en) * 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
ES2833506T3 (es) * 2014-12-22 2021-06-15 Ares Trading Sa Composición farmacéutica líquida
US9672719B1 (en) 2015-04-27 2017-06-06 State Farm Mutual Automobile Insurance Company Device for automatic crash notification
CN104940902B (zh) * 2015-05-29 2018-08-10 北京凯因科技股份有限公司 一种聚乙二醇集成干扰素变异体的稳定溶液
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017007837A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilizaton of proteins
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US10961314B2 (en) * 2016-09-27 2021-03-30 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody
EA201990998A1 (ru) * 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения
EP3533441A4 (en) 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
JP7109849B2 (ja) * 2017-03-16 2022-08-01 エルジー・ケム・リミテッド 抗ＴＮＦα抗体の液状製剤
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
CA3085158C (en) * 2017-12-22 2023-04-04 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
WO2019212429A2 (en) * 2018-05-04 2019-11-07 İlkogen İlaç Sanayi̇ Ve Ti̇caret A.Ş. Stable hybrid fc fusion g-csf formulation
JP7467438B2 (ja) * 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
MXPA04008215A (es) 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2004262014B2 (en) * 2003-08-01 2010-06-17 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
SI21639A (sl) 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
JP5554466B2 (ja) * 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
GB0506708D0 (en) 2005-04-01 2005-05-11 Queen Mary & Westfield College Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
DE202005006130U1 (de) 2005-04-12 2005-08-25 Fasys Bauservice Gmbh Anordnung zur optischen Warnung vor Fahrdrähten
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EA200870538A1 (ru) 2006-06-14 2009-04-28 Имклоун Системз Инкорпорейтед Лиофилизированные композиции анти-egfr антител
CA2674608A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP2009155329A (ja) * 2007-12-07 2009-07-16 Kyowa Hakko Kirin Co Ltd 上皮細胞成長因子受容体ファミリーに対する抗体またはその機能的断片およびそれらを含有する癌を治療するための医薬組成物
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2008361352B2 (en) * 2008-09-07 2013-05-09 Glyconex Inc. Anti-extended Type I glycosphingolipid antibody, derivatives thereof and use
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
SG10201703707YA (en) 2009-03-19 2017-06-29 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
ES2684921T3 (es) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
CA2833427C (en) 2011-04-20 2019-09-24 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein tnfr:fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept

Also Published As

Publication number Publication date
CO6852068A2 (es) 2014-01-30
EA201391739A1 (ru) 2014-05-30
US20140199303A1 (en) 2014-07-17
KR20120135387A (ko) 2012-12-13
JP2016145192A (ja) 2016-08-12
IL229787A (en) 2016-10-31
MX354297B (es) 2018-02-23
RU2013156112A (ru) 2015-07-20
HUE037031T2 (hu) 2018-08-28
US10258689B2 (en) 2019-04-16
NZ618054A (en) 2016-06-24
CN104623656A (zh) 2015-05-20
CA2837176A1 (en) 2012-12-06
TW201311293A (zh) 2013-03-16
MY173907A (en) 2020-02-27
CN104623656B (zh) 2018-05-29
CL2013003461A1 (es) 2014-06-06
ZA201308659B (en) 2015-06-24
BR112013031112A2 (pt) 2016-11-29
AU2012263100B2 (en) 2016-04-14
ES2645969T3 (es) 2017-12-11
BR112013031112A8 (pt) 2017-10-24
EP2714009A1 (en) 2014-04-09
AU2012263100A1 (en) 2013-12-12
EP2714009B1 (en) 2017-08-23
UA113172C2 (uk) 2016-12-26
CA2837176C (en) 2017-05-16
KR101482304B1 (ko) 2015-01-14
TW201540322A (zh) 2015-11-01
WO2012165917A1 (en) 2012-12-06
JP5918850B2 (ja) 2016-05-18
EP2714009A4 (en) 2014-11-26
KR20140122213A (ko) 2014-10-17
HK1204921A1 (en) 2015-12-11
EA028947B1 (ru) 2018-01-31
CN103619324A (zh) 2014-03-05
AR086658A1 (es) 2014-01-15
MA35186B1 (fr) 2014-06-02
JP2014522402A (ja) 2014-09-04
MX2013014027A (es) 2014-04-16
SG195054A1 (en) 2013-12-30
TWI548424B (zh) 2016-09-11
TN2013000493A1 (en) 2015-03-30

Similar Documents

Publication Publication Date Title
UY34105A (es) Formulación líquida estable de etanercept
SMT201600108B (it) Derivato di pirazochinolina come inibitori di pde9
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay
BR112015003095A2 (pt) composições líquidas contendo inibidores de urease e aril-alquila álcoois
UY34836A (es) Nuevo organismos
UY34209A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
CO6821943A2 (es) Moduladores de receptores de glucocorticoides de pirimidina ciclohexilo
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
UY34221A (es) Quinolinas sustituidas inhibidoras de la proteina syk quinasa y su uso como medicamentos
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34141A (es) Composiciones de limpieza de sal líquida
SMT201600001B (it) Imidazopiridazine come inibitori di akt chinasi
UY33930A (es) Inhibidores novedosos de quinasas
CO7091177A2 (es) Inhibidores de la beta-secretasa
UY33977A (es) Híbrido de pigmento autoaglutinante.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
UY34158A (es) Composicion herbicida
BR112014003027A2 (pt) formulação herbicida melhorada
CR20140528A (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20211216